Canine otitis externa can be painful for patients – but fast relief with an easy-to-administer treatment is possible

Treating canine patients with EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs is proven to deliver fast relief as early as 24 hours.¹

Otitis externa (OE) is a common problem in dogs – it’s ranked as the #2 reason dog owners bring their pet to the clinic.² OE is painful for dogs and stressful for pet owners, which can affect the human-animal bond. Pet owners may feel relief takes too long and treatment is difficult to administer correctly on their own.¹

EASOTIC Otic Suspension for Dogs: Fast relief in just 24 hours¹

EASOTIC Otic Suspension features a low risk of systemic side effects with 3 proven active ingredients:^3-5

• Hydrocortisone Aceponate (HCA)
  • Powerful and unique anti-inflammatory with a positive benefit-risk ratio.³
  • Diester topical steroid that is rapidly absorbed for quick, effective dose concentrations in the epidermis and dermis.^3,5
• Gentamicin
  • Broad-spectrum antimicrobial^6,7 with an established safety profile.⁸
• Miconazole
  • Broad-spectrum antifungal with proven, consistent results.^6,9,10

EASOTIC Otic Suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius). The safety and benefit/risk profile of hydrocortisone aceponate allows EASOTIC Otic Suspension to be administered at more than twice the total delivered dose of other Class III glucocorticoids such as mometasone.

For example:

• EASOTIC Otic Suspension delivers 5,550 μg (mcg) of anti-inflamatory steroid over the course of treatment.⁴
• CLARO® Otic Solution for dogs (florfenicol, terbinafine and mometasone furoate) delivers 2,200 μg of a steroid with similar potency.

Head-to-head treatment challenge

A multicentric randomized post-marketing study was used to compare EASOTIC Otic Suspension to a popular single-dose competitor product, CLARO®.¹¹

During the 28-day post-marketing study, 80 dogs were randomly assigned to two groups – EASOTIC Otic Suspension (41 dogs) and CLARO (39 dogs). Both groups were evaluated and treated per each product’s label instructions. Here are the results when compared to CLARO:

• Day 2: EASOTIC Otic Suspension showed statistically significant differences on improvement of signs like discharge, stenosis and odor.^1,11
• Day 7: 49% percent of EASOTIC Otic Suspension-treated patients showed “Excellent” treatment response as rated by veterinarians. CLARO patients showed 29%.¹¹
• Day 28: 76% of EASOTIC Otic Suspension patients showed “Excellent” treatment response. CLARO showed 44%.¹¹

The benefits for pet owners

Administering EASOTIC Otic Suspension also provides a better experience for pet owners. Its ergonomically designed applicator makes applying the dose simpler and less traumatic for the dog.¹² The airless bottle prevents retro contamination and allows accurate dosing at any angle, even upside down. In a customer experience survey, 93% of dog owners found the product easy to use, and 88% of veterinarians were satisfied with the results.^1*

Results from the survey show that pet owners observed fast relief starting as early as 24 hours after the first dose.¹

A strong foundation for ear health

Routine cleaning is essential to helping maintain your patients’ ear health at home. Compliance can be challenging for pet owners, so there is a need for a product that’s effective yet comfortable enough to use routinely in their dogs’ ears.

EPIOTIC® Advanced Ear Cleanser is a powerful and gentle cleanser that’s ideal for dogs who frequently deal with allergies, swim or get wet often and also dogs with floppy ears.

Here are the benefits of recommending EPIOTIC Advanced Ear Cleanser to pet owners:

• Features a nonirritating, neutral pH formula.
• Keeps ears clean, healthy and smelling fresh.
• Gentle enough for everyday use on all dogs, including puppies.

Because of these factors, EPIOTIC Advanced Ear Cleanser was recently named Best Overall Dog Ear Cleaner by Business Insider. In their positive review, Business Insider said, “It contains a solid combination of ingredients while being gentle enough for daily use.” Read the article here.

A deeper conversation about the OE landscape

Compliance and the caregiver burden – OE treatment presents many challenges for dogs, pet owners and veterinarians alike. There are many products with different benefits, lengths of treatment, ease of use and effectiveness. Which should you stock in your clinic?

In the webinar “Otitis Externa: Treatment Frustrations and Potential Solutions,” Mike Kirkpatrick, DVM, discusses otitis externa and explores evidence-based treatment approaches to get the fast relief pet owners need. Dive into the evidence and rethink your approach to otitis externa.

View the webinar by visiting: https://vet-us.virbac.com/home/learning-and-resources/otitis-externa-ce.html

For Full Prescribing Information, please see bit.ly/4aKMrPb

References

1. Data on file. Virbac Corporation.
2. Dermatitis, otitis externa among top pet insurance claims. Veterinary Practice News. April 13, 2023. https://www.veterinarypracticenews.com/dermatitis-otitis-externa-among-top-pet-insurance-claims.
3. Schäfer-Korting M, Gysler A. Topical glucocorticoids with improved benefit/risk ratio. In: Korting HC, Schäfer-Korting M, eds. The Benefit/Risk Ratio: A Handbook for The Rational Use of Potentially Hazardous Drugs. Boca Raton, FL: CRC Press; 1999:359-372.
4. Guaguère E, Bensignor E, Carlotti D-N, et al. Clinical practice guidelines on the best use of topical glucocorticoids in canine dermatology. Prat Med Chir Anim Comp. 2011;46:S1-S20. doi:10.1016/S0758-1882(11)70001-2.
5. Schackert C, Korting HC, Schäfer-Korting M. Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo: characterisation of drugs with an increased benefit-risk ratio. BioDrugs. 2000;13(4):267-277. doi:10.2165/00063030-200013040-00005.
6. Lyskova P, Vydrzalova M, Mazurova J. Identification and antimicrobial susceptibility of bacteria and yeasts isolated from healthy dogs and dogs with otitis externa. J Vet Med A Physiol Pathol Clin Med. 2007;54(10):559-563.doi:10.1111/j.1439-0442.2007.00996.x.
7. Hariharan H, McPhee L, Heaney S, Bryenton J. Antimicrobial drug susceptibility of clinical isolates of Pseudomonas aeruginosa. Can Vet J. 1995;36(3):166-168.
8. Strain GM, Merchant SR, Neer TM, Tedford BL. Ototoxicity assessment of a gentamicin sulfate otic preparation in dogs. Am J Vet Res. 1995;56(4):532-538.
9. Rigaut D, Sanquer A, Maynard L, Rème CA. Efficacy of a topical ear formulation with a pump delivery system for the treatment of infectious otitis externa in dogs: a randomized controlled trial. Intern J Appl Res Vet Med. 2011;9(1):15-28.
10. Barasch A, Griffin AV. Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. Future Microbiol. 2008;3(3):265-269.doi:10.2217/17460913.3.3.265.
11. von Simson C, Poincelot L, Jasmin P, Griffin J. Comparison of the efficacy of a gentamicin, miconazole and hydrocortisone aceponate formulation and a florfenicol, terbinafine and mometasone furoate formulation in the treatment of canine otitis externa with a focus on onset of action. Abstract presented at: World Congress of Veterinary Dermatology; July 25-29, 2024; Boston, MA.
12. Boda C, Liège P, Rème CA. Evaluation of owner compliance with topical treatment of acute otitis externa in dogs: a comparative study of two auricular formulations. Intern J Appl Res Vet Med. 2011;9(2):157-165.

*Product administered once daily for 5 days in dogs with otitis externa. Pet owners provided ratings on days 1, 2, 5 and 14. Veterinarians provided evaluations on day 1 and at the recheck appointment between days 14 and 28.

©2026 Virbac Corporation. All rights reserved. EASOTIC and EPIOTIC are registered trademarks of the Virbac Group of Companies. All other trademarks are the property of their respective owners. 8/26